Work

Supplementary Figure 3 from A Phase II and Biomarker Study of Ramucirumab, a Human Monoclonal Antibody Targeting the VEGF Receptor-2, as First-Line Monotherapy in Patients with Advanced Hepatocellular Cancer

Year: 2023

Type: supplementary-materials

Abstract: PDF file - 76K, Fold changes in biomarker levels relative to baseline following ramucirumab infusion across study cycles. Each line indicates values for a single patient.

DOI: 10.1158/1078-0432.22448427

Authors: Andrew X. Zhu, Richard S. Finn, Mary Mulcahy, Jayne Gurtler, Weijing Sun, Jonathan D. Schwartz, Rita P. Dalal, Adarsh Joshi, Rebecca R. Hozak, Yihuan Xu, Marek Ancukiewicz, Rakesh K. Jain, Francis W. Nugent, Dan G. Duda, Keith Stuart

Language: English

Topic: Hepatocellular Carcinoma Treatment and Prognosis

Subfield: Hepatology

Field: Medicine

Domain: Health Sciences

SDG: Good health and well-being

Open Access status: gold

OpenAlex ID: W4362394780

Cites:

Cited by:

Related to: 10